Anji Pharma, a Cambridge , MA - Shanghai in-licensing company, closed a $70 million Series B financing to seed its oncology pipeline and continue global trials of its two metabolic assets. CR Capital, the VC arm of China Resources, was the only investor in the round. Anji conducts joint US-China clinical trials of its candidates. The company uses a "dynamic equity" approach to its joint venture partnerships, aiming to make smaller upfront payments for the candidates, and then earning additional equity for milestones and sharing development responsibility with the originator company. More details.... Share this with colleagues: // //